{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Shattuck Labs, Inc."},"Symbol":{"label":"Symbol","value":"STTK"},"Address":{"label":"Address","value":"500 W. 5TH STREET,SUITE 1200, AUSTIN, Texas, 78701, United States"},"Phone":{"label":"Phone","value":"+1 512 900-4690"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor."},"CompanyUrl":{"label":"Company Url","value":"https://www.shattucklabs.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Abhinav A. Shukla","title":"Chief Technology Officer"},{"name":"Amy Franke","title":"Vice President-Clinical Operations"},{"name":"Lini Pandite","title":"Chief Medical Officer"},{"name":"Taylor H. Schreiber","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}